By Blair Childs, Senior Vice President of Public Affairs
Today’s actions by the Senate Judiciary Committee to advance S. 1425 and S. 1428 are important first steps in lowering drug prices. The need to thwart anti-competitive practices that interfere with the approval of a competing generic drug or biosimilar, as well as addressing misaligned incentives that artificially inflate drug prices, have been long overdue. These commonsense bills reward innovation while also holistically lowering drug prices for all segments of healthcare, including the consumer. Premier looks forward to working with Congress to advance these bills.